NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/29/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization283.17 mln
Float55.60 mln
Earnings Date08/11/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-2.51
Likely reliable
1-Year Forecast
6.75
Transformational upside
Relative Strength
38
/ 100
Underperforming
Debt / Equity
1.72
High leverage
ROE
-131
Deeply negative
Business Description
MacroGenics is a US-based biopharmaceutical company focused on developing antibody-based treatments for cancer. Its pipeline includes several promising therapies, ranging from molecules that help the immune system attack tumors to antibody-drug conjugates that deliver targeted payloads directly to cancer cells, with programs spanning early research through active clinical trials. The company works alongside partners such as Incyte Corporation and Gilead Sciences to advance its treatments. Founded in 2000 and based in Rockville, Maryland, MacroGenics continues to build on its expertise in antibody engineering to address a range of difficult-to-treat cancers.
